Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin and prostacyclin.

M Camici1, L Evangelisti

  • 12nd Medical Clinic, University Hospitals, Pisa, Italy.

Angiology
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Prostacyclin can replace heparin for anticoagulation during hemodialysis. Combining prostacyclin with heparin enhances its anticoagulant effect and increases antithrombin activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing intra- and inter-molecular interactions through rotational spectroscopy: The case of the odorant 2'-aminoacetophenone and its 1:1 water and neon complexes.

The Journal of chemical physics·2022
Same author

Ocular involvement in monkeypox: Description of an unusual presentation during the current outbreak.

The Journal of infection·2022
Same author

A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II.

The international journal of biochemistry & cell biology·2015
Same author

The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.

Biochemical pharmacology·2015
Same author

Unexpected death of a ventilator-dependent amyotrophic lateral sclerosis patient.

Revista portuguesa de pneumologia·2013
Same journal

Refining Phenotype-Based Interpretation of SGLT2 Inhibitors After AMI Without Heart Failure.

Angiology·2026
Same journal

Response to: "Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary Arteries".

Angiology·2026
Same journal

Response to: "Beyond Traditional Risk Markers: Is FIB-4 Sufficient in MINOCA?"

Angiology·2026
Same journal

Letter: Further Considerations on the Clinical Use of the Scottish Inflammatory Prognostic Score in STEMI No-Reflow Prediction.

Angiology·2026
Same journal

Contextualizing Remodeling Endpoints in Endovascular Treatment for Symptomatic SISMAD.

Angiology·2026
Same journal

<i>Response to the Letter to the Editor</i>: "Effect of Invasive Hemodynamic Monitoring on the Outcomes of Cardiogenic Shock in Patients With Acute Myocardial Infarction".

Angiology·2026
See all related articles

Area of Science:

  • Nephrology
  • Pharmacology
  • Hematology

Background:

  • Heparin is the standard anticoagulant for hemodialysis.
  • Heparin use can be limited by side effects and variable patient response.
  • Alternative anticoagulation strategies are needed to optimize hemodialysis procedures.

Purpose of the Study:

  • To evaluate prostacyclin as a substitute for heparin in hemodialysis.
  • To investigate the combined effects of prostacyclin and heparin on anticoagulation.
  • To assess the impact on plasma antithrombin levels and activated partial thromboplastin time.

Main Methods:

  • Studied 10 patients undergoing hemodialysis.
  • Administered prostacyclin (5 ng/kg/min) as a heparin substitute.
  • Compared heparin alone versus combined heparin and prostacyclin regimens.

Related Experiment Videos

  • Measured plasma antithrombin levels and activated partial thromboplastin time.

    • Main Results:

    • Prostacyclin effectively substituted for heparin anticoagulation.
    • Concomitant prostacyclin administration potentiated heparin's anticoagulant effect.
    • Both treatments increased antithrombin activity, with prostacyclin showing a greater effect.
    • Platelet activation influences heparin's anticoagulant efficacy.

    Conclusions:

    • Prostacyclin offers a viable alternative to heparin for hemodialysis anticoagulation.
    • Combination therapy with prostacyclin and heparin enhances anticoagulation.
    • Understanding platelet activation is crucial for optimizing heparin therapy.